ChemLifeIntel/Companies/Merck Receives EC

Merck Receives EC

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 7 of 7 briefs on Merck Receives EC

MARKET INTELLIGENCE·CDMO Deal

Merck's Alimatravir Licensing Reshapes HIV PrEP Market Access Ahead of Regulatory Approval

Merck's voluntary licensing of alimatravir for HIV PrEP, preceding regulatory submissions, signals a proactive market access strategy mirroring Gilead. This move impacts global supply chains by diversifying manufacturing potential and accelerates patient access. Procurement directors must prepare for multi-source API strategies, while regulatory affairs heads should anticipate complex, staggered approvals and market entry. Business development executives should evaluate this model for pipeline assets.

90-Day Activity

Merck Receives ECalimatravir

RARobert Ashworth· Principal Intelligence Analyst

4d ago CDMO Deal

CLINICAL & PIPELINE·Drug Approval

Merck's Lipfendra Secures FDA Approval as First Oral PCSK9 Inhibitor, Unlocking $5 Billion Hypercholesterolemia Market

Merck's Lipfendra has received FDA approval on July 16, 2026, marking the first oral PCSK9 inhibitor for hypercholesterolemia. This approval creates a significant commercial opportunity, with market potential estimated at $5 billion, profoundly impacting cardiovascular treatment paradigms. Procurement and supply chain leaders must evaluate new sourcing strategies for this oral formulation, while regulatory and business development teams will navigate evolving market access dynamics.

90-Day Activity

Merck Receives EC

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

8d ago Drug Approval

CLINICAL & PIPELINE·Drug Approval

Merck's Lipfendra: First Oral PCSK9 Inhibitor Reshapes Hypercholesterolemia Market with $5 Billion Potential

Merck's FDA approval of Lipfendra, the first oral PCSK9 inhibitor for hypercholesterolemia, marks a significant shift in cardiovascular treatment. With a projected peak annual sales potential of $5 billion, this approval presents substantial commercial and supply chain opportunities for Merck, demanding robust manufacturing and strategic market access planning to capitalize on its novel oral formulation.

90-Day Activity

Merck Receives ECLipfendra

RMRohan Mehta· Senior Supply Chain Intelligence Analyst

12d ago Drug Approval

CLINICAL & PIPELINE·Drug Approval

FDA Approves Merck and Gilead's Trodelvy-Keytruda Combination for PD-L1+ Metastatic TNBC

The FDA has approved Merck and Gilead's Trodelvy plus Keytruda for previously untreated PD-L1 positive metastatic Triple-Negative Breast Cancer. This approval, based on strong Phase III data, establishes a new first-line standard of care, significantly impacting market access, competitive dynamics, and supply chain strategies for both pharmaceutical giants in the oncology sector.

90-Day Activity

Merck Receives EC

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

2026-06-25 Drug Approval

CLINICAL & PIPELINE·Drug Approval

Merck's Padcev-Keytruda Combination Secures EC Approval for MIBC: Supply Chain and Market Access Implications

Merck has secured European Commission approval for its perioperative Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) combination for resectable muscle-invasive bladder cancer (MIBC) in cisplatin-ineligible patients across 30 EEA states. This approval, based on robust Phase III data, establishes a new standard of care, significantly impacting market access strategies, API procurement, and competitive dynamics within the European oncology landscape for Merck and its partners.

90-Day Activity

Merck Receives EC

PSPriya Subramaniam· Intelligence Analyst

2026-06-24 Drug Approval

CLINICAL & PIPELINE·Drug Approval

Merck Sharp & Dohme's STEGLUJAN: Regulatory Milestones for Ertugliflozin and Sitagliptin Combination

Merck Sharp & Dohme LLC secured the original NDA approval for STEGLUJAN (ertugliflozin and sitagliptin) on December 19, 2017, as a new combination therapy. Subsequent FDA approvals for labeling and efficacy supplements have consistently updated the product's regulatory profile. This ongoing regulatory activity underscores Merck's commitment to refining product information and market positioning for this critical diabetes medication, impacting procurement and competitive strategies.

90-Day Activity

Merck Receives ECSTEGLUJAN

PSPriya Subramaniam· Intelligence Analyst

2026-06-03

CLINICAL & PIPELINE·Drug Approval

Merck's NOXAFIL (Posaconazole) Secures Key FDA Labeling Update, Strategic Orphan Designation Pending

MSD MERCK CO secured FDA approval for a significant labeling supplement for NOXAFIL (POSACONAZOLE) on October 25, 2024, enhancing market clarity. This follows the original NDA approval in May 2021 and precedes an efficacy supplement with Orphan designation in January 2026. This trajectory signals sustained investment in the azole antifungal, impacting procurement strategies and long-term market positioning for this critical medication.

90-Day Activity

Merck Receives ECNoxafil Powdermix

PSPriya Subramaniam· Intelligence Analyst

2026-01-27